Cleave adds $10m to Series A for cancer drugs

Cleave Biosciences has added $10 million to the $44 million Series A round that the Burlingame, California-based company raised in 2011 to move its first lead oncology compound into the clinic this year and advance a second cancer drug discovery program.

Cleave Biosciences has added $10 million to the $44 million Series A round that the Burlingame, California-based company raised in 2011 to move its first lead oncology compound into the clinic this year and advance a second cancer drug discovery program.

New Enterprise Associates (NEA) joined the long list of venture capital firms who financed Cleave a year and a half...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category